vialroom

#dosing-titration 2026-01-28

Wednesday15 messages3 participantstimes are UTC
Highlights from this day
  • igf_one_ivy — plateau versus set point is not answerable in under six months of data 19:57
  • meniscus_mel — genuine question came down from a treatment dose to maintenance over about three months and it was uneventful, anyway 19:58
  • meniscus_mel — for the archive the argument for splitting is a flatter curve. the argument against is you have doubled your injections for a guess, i think plateau versus set point… 20:11
  • igf_one_ivy — update on the earlier thing appetite returning at the end of the week is extremely common and is not the dose failing 20:33

thats normal

thats noise

Cited study
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 2022
72 weeks, tirzepatide 5, 10 and 15mg against placebo.

plateau versus set point is not answerable in under six months of data

Cited study
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 2022
72 weeks, tirzepatide 5, 10 and 15mg against placebo.
MM

genuine question came down from a treatment dose to maintenance over about three months and it was uneventful, anyway

📉1
MM

for the archive the argument for splitting is a flatter curve. the argument against is you have doubled your injections for a guess, i think
plateau versus set point is not answerable in under six months of data

stepping back down on purpose is a completely reasonable move and this channel should say so more often

the honest answer is that most of us are running protocols nobody has ever studied

[edited]
IO

update on the earlier thing appetite returning at the end of the week is extremely common and is not the dose failing

MM

split dosing has no trial behind it. people here do it and report on it, thats all